Ignite Creation Date:
2025-12-17 @ 4:49 PM
Ignite Modification Date:
2025-12-24 @ 4:06 AM
Study NCT ID:
NCT00788294
Status:
COMPLETED
Last Update Posted:
2020-10-06
First Post:
2008-11-07
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
Sponsor:
Pfizer
Organization:
Study Overview
Official Title:
Pharmacokinetics And Safety Of A Single Dose Subcutaneous Or Intravenous Administration Of Tanezumab In Healthy Volunteers: An Open-Label, Non-Randomized Phase 1 Study
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: